US Regulatory Roundup, December 2018: A Guilty Plea, And A Changing Regulatory Landscape
Executive Summary
The closing months of 2018 have turned out to be a dynamic period for the US medtech regulatory community. Journalists turned significant scrutiny toward FDA's oversight of the sector, even as the agency moved full steam ahead with important policy reforms. These issues are reflected in Medtech Insight's most popular US regulatory and policy articles in December.